We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Department of Neurology and Psychiatry & Biobehavioral Sciences, Davids Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email: [email protected]
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
Cummings, J.L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds.American Journal of Psychiatry, 157, 4–15.Google Scholar
Cummings, J.L. (2003). Toward a molecular neuropsychiatry of neurodegenerative disease.Annals of Neurology, 54, 147–154.Google Scholar
Cummings, J.L. (2004). Alzheimer's disease.New England Journal of Medicine, 351, 56–67.Google Scholar
Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease.New England Journal of Medicine, 351, 2509–2518.Google Scholar
Jacobs, B.L., Praag, H.V., Gage, F.H., et al. (2000). Adult brian neurogenesis and psychiatry: a novel theory of depression.Molecular Psychiatry, 5, 262–269.Google Scholar
Klunk, W.E., Engler, H., Nordberg, A., et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B.Annals of Neurology, 55, 306–319.Google Scholar
Lee, C.J., Lee, L.H., Lu, C., et al. (2003). Development and Evaluation of Drugs (2nd edn.).CRC Press, Boca Raton, Florida.
Ng, R. (2004). Drugs from Discovery to Approval.Wiley-Liss, Hoboken, New Jersey.